clinical trial · NCT06858319
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
Kidney DiseasesKidney Diseases, ChronicUrological DiseasesGlomerulonephritisGlomerular DiseaseGlomerulonephritis, IGAGlomerulopathyImmunoglobulin Diseasezigakibart
brief summary
The purpose of this study is to determine if zigakibart is safe and effective for long-term use in patients with immunoglobulin A nephropathy (IgAN). This is an extension study for patients who have already completed an another zigakibart study.
started
Jul 28, 2025
primary completion
Jun 25, 2031
completion
Jun 25, 2031
last updated
Feb 6, 2026
detailed description
This is a non-randomized, multicenter, open-label extension (OLE) study to Phase 3, randomized CHK02-02 (CFUB523A12301)-BEYOND clinical study, Phase 1/2 ADU-CL-19 (CFUB523A12103) clinical study, and any other Novartis-sponsored clinical study of zigakibart in IgAN.
official title
A Multicenter Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Zigakibart in Adults With Primary IgA Nephropathy.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol